首页> 外文期刊>Pathology International >Frequent EGFR expression/ EGFR EGFR amplification and lack of activating mutation in testicular choriocarcinoma
【24h】

Frequent EGFR expression/ EGFR EGFR amplification and lack of activating mutation in testicular choriocarcinoma

机译:频繁EGFR表达/ EGFR EGFR扩增和缺乏睾丸胆碱癌中的激活突变

获取原文
获取原文并翻译 | 示例
           

摘要

Choriocarcinoma (CC) is the rarest but most aggressive histological component of adult testicular germ cell tumor (TGCT). Although we previously reported a putative role of epidermal growth factor receptor (EGFR) alterations in the progression of CC, little is known about the kinase‐activating mutation status of EGFR , which predicts the response to EGFR‐tyrosine kinase inhibitors. In this study, we clinicopathologically reviewed a total of 12 cases of mixed TGCTs with CC components. Immunohistochemistry, fluorescence in situ hybridization, and direct sequencing was performed to investigate EGFR expression, EGFR copy number alterations, and functional mutation of EGFR in these CC components, respectively. Four (33%) of 12 cases exhibited predominant CC components (50%), and all these patients died due to disease within 62 months. Overexpression of EGFR, higher copy number of EGFR , and amplification of EGFR was observed in 12 (100%), 10 (83%), and 9 (75%) of 12 CC components, respectively. None of the cases showed any mutational events in exons 18 to 24, which encode the tyrosine kinase domain of EGFR . These results confirm an important role of EGFR in the tumor aggressiveness of testicular CCs and may suggest its possible innate resistance against conventional anti‐EGFR therapies.
机译:Choriocarcinoma(CC)是成人睾丸生殖细胞肿瘤(TGCT)的最罕见但最具侵略性的组织组分。虽然我们之前报道了表皮生长因子受体(EGFR)在CC进展中的改变的推定作用,但关于EGFR的激酶活化突变状态几乎是已知的,这预测了对EGFR-酪氨酸激酶抑制剂的反应。在这项研究中,我们临床病理学综述了12例与CC组分的混合TGCT。进行免疫组织化学,原位杂交的荧光,并进行直接测序,以调查本CC组分中EGFR的EGFR表达,EGFR拷贝数改变和功能突变。四种(33%)的12例表现出主要的CC组分(& 50%),所有这些患者因疾病死于62个月内。 EGFR的过表达,在12(100%),10(83%)和9个(75%)的12个CC组分中观察到更高拷贝的EGFR和EGFR的扩增。这些病例中没有一个在外显子18至24中显示任何突变事件,其编码EGFR的酪氨酸激酶结构域。这些结果证实了EGFR在睾丸CCS肿瘤侵略性中的重要作用,并且可能表明其可能对抗常规抗EGFR疗法的先天性抵抗力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号